PRV-3279-2a Trial in Systemic Lupus (PREVAIL-2)

First posted October, 2021, Updated January, 2022; Recruiting

The purpose of this Phase 2a PREVAIL-2 trial is to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) patients with active disease after amelioration induced by corticosteroid treatment.

To Learn More Contact

Clinical Operations at 857-675-1664 or email

Chief Medical Officer at 908-356-0514 or email identifier (NCT number): NCT05087628

Sign up for our Newsletter

Use this tool to search all lupus trials and create a personalized list of studies by the type of lupus you have and where you live.

Sign up